Identification

Name
Dexamethasone
Accession Number
DB01234  (APRD00674)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]

Structure
Thumb
Synonyms
  • 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
  • 1-Dehydro-16α-methyl-9α-fluorohydrocortisone
  • 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
  • 16α-Methyl-9α-fluoro-1-dehydrocortisol
  • 9alpha-Fluoro-16alpha-methylprednisolone
  • 9α-Fluoro-16α-methylprednisolone
  • Dexametasona
  • Dexamethasone
  • Dexamethasonum
External IDs
NSC-34521
Product Ingredients
IngredientUNIICASInChI Key
Dexamethasone acetateK7V8P532WP1177-87-3AKUJBENLRBOFTD-RPRRAYFGSA-N
Dexamethasone phosphate2BP70L44PR312-93-6VQODGRNSFPNSQE-CXSFZGCWSA-N
Dexamethasone sodium phosphateAI9376Y64P2392-39-4PLCQGRYPOISRTQ-FCJDYXGNSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accufix II Dec Model 033-212Implant.7 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Decadron Phosphate Eye Ear Sol 0.1%Liquid1 mgAuricular (otic); OphthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1960-12-311998-04-21Canada
Decadron Phosphate Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-08-01Canada
Decadron Tab 0.5mgTablet.5 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1958-12-312002-07-29Canada
Decadron Tab 4mgTablet4 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-08-08Canada
DexamethasoneSolution0.1 %Auricular (otic); OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Dexamethasone Omega UnidoseSolution10 mgIntramuscular; Intrasynovial; IntravenousOmega Laboratories Ltd2013-05-08Not applicableCanada
Dexamethasone Sod Phos Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousTaro Pharmaceuticals, Inc.1989-12-312001-08-21Canada
Dexamethasone Sod Phosph Inj 10mg/ml USPLiquid10 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada Incorporated1990-12-31Not applicableCanada
Dexamethasone Sodium Phosphate 0.1%Solution / drops.1 %Auricular (otic); OphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dexamethasoneTablet0.5 mgOralApotex Corporation2004-11-17Not applicableCanada
Apo-dexamethasoneTablet4 mgOralApotex Corporation2004-03-08Not applicableCanada
BaycadronElixir.5 mg/5mLOralWockhardt1983-07-27Not applicableUs
DecadronTablet1.5 mg/1OralWraser Llc2017-09-112017-09-29Us
Decadron DPTablet1.5 mg/1OralXspire Pharma, Llc2017-09-112017-09-29Us
DexamethasoneTablet.5 mg/1OralWest Ward Pharmaceutical1975-07-25Not applicableUs
DexamethasoneTablet6 mg/1OralPar Pharmaceutical1983-11-282017-05-02Us
DexamethasoneTablet4 mg/1OralProficient Rx LP1978-07-19Not applicableUs
DexamethasoneElixir.5 mg/5mLOralMorton Grove Pharmaceuticals, Inc.1983-07-27Not applicableUs
DexamethasoneTablet6 mg/1OralWest Ward Pharmaceutical1983-09-15Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dmt SuikInjection, solution10 mg/mLIntramuscular; IntravenousAsclemed Usa, Inc.2003-05-29Not applicableUs
International/Other Brands
Decadron (Sidus)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
999 Itch ReliefDexamethasone (15 mg/20000mg) + Camphor (200 mg/20000mg) + Menthol (200 mg/20000mg)OintmentTopicalChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Physicians Total Care, Inc.2004-09-21Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Clinical Solutions Wholsesale2003-08-152017-07-01Us
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Rebel Distributors2003-08-15Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)Suspension / dropsAuricular (otic)Alcon, Inc.2003-08-04Not applicableUs
CiprodexDexamethasone (0.1 %) + Ciprofloxacin (0.3 %)SuspensionAuricular (otic)Novartis2004-05-13Not applicableCanada
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)Suspension / dropsAuricular (otic)Nu Care Pharmaceuticals,inc.2003-08-04Not applicableUs
Cresophene LiqDexamethasone (1 mg) + Camphor (649 mg) + Parachlorophenol (300 mg) + Thymol (50 mg)LiquidDentalSeptodont1978-12-31Not applicableCanada
Dioptrol OintmentDexamethasone (1 mg) + Neomycin sulfate (3.5 mg) + Polymyxin B Sulfate (10000 unit)OintmentOphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Dioptrol SuspensionDexamethasone (1 mg) + Neomycin (3.5 mg) + Polymyxin B Sulfate (10000 unit)SuspensionOphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Categories
UNII
7S5I7G3JQL
CAS number
50-02-2
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
UREBDLICKHMUKA-CXSFZGCWSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps

Structured Indications
Pharmacodynamics

Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.

Mechanism of action

Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UNuclear receptor subfamily 0 group B member 1
stimulator
Human
UAnnexin A1
agonist
Human
UNitric oxide synthase, inducible
negative modulator
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption

80-90%

Volume of distribution
Not Available
Protein binding

70%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

36-54 hours

Clearance
Not Available
Toxicity

Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Dexamethasone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dexamethasone.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexamethasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Dexamethasone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Dexamethasone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Dexamethasone.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dexamethasone.Experimental
AlbendazoleThe serum concentration of Dexamethasone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Dexamethasone.Approved, Withdrawn
AldesleukinDexamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Dexamethasone.Experimental
AlectinibThe serum concentration of Dexamethasone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Dexamethasone can be increased when it is combined with Alfentanil.Approved, Illicit
AlgeldrateThe bioavailability of Dexamethasone can be decreased when combined with Algeldrate.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Dexamethasone.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Dexamethasone.Investigational
AlmagateThe bioavailability of Dexamethasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Dexamethasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Dexamethasone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.Approved
AloglutamolThe bioavailability of Dexamethasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Dexamethasone.Experimental
AluminiumThe bioavailability of Dexamethasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Dexamethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Dexamethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved
AmantadineThe serum concentration of Dexamethasone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dexamethasone.Approved, Investigational
Aminohippuric acidThe serum concentration of Dexamethasone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone.Approved
AmiodaroneThe metabolism of Dexamethasone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.Approved
AmlodipineThe serum concentration of Dexamethasone can be increased when it is combined with Amlodipine.Approved
Amphotericin BDexamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Dexamethasone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Dexamethasone can be increased when it is combined with Amsacrine.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dexamethasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dexamethasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Dexamethasone.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Dexamethasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexamethasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Dexamethasone.Approved, Investigational
AprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.Approved, Investigational
AsparaginaseThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.Approved
Asparaginase Erwinia chrysanthemiThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.Approved
AstemizoleThe serum concentration of Dexamethasone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Dexamethasone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Dexamethasone.Approved
AtomoxetineThe metabolism of Dexamethasone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone.Withdrawn
AzelastineThe serum concentration of Dexamethasone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Dexamethasone can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Dexamethasone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dexamethasone.Investigational
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Dexamethasone.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Dexamethasone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Dexamethasone.Experimental
BendroflumethiazideDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Dexamethasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexamethasone.Withdrawn
BenzocaineThe serum concentration of Dexamethasone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Dexamethasone.Approved
BepridilThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Dexamethasone.Experimental
BiperidenThe serum concentration of Dexamethasone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Dexamethasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Dexamethasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Dexamethasone can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Dexamethasone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dexamethasone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexamethasone.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dexamethasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Dexamethasone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dexamethasone.Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Dexamethasone.Experimental
BumetanideDexamethasone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Dexamethasone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Dexamethasone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexamethasone.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dexamethasone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Dexamethasone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Dexamethasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Dexamethasone can be decreased when combined with Calcium silicate.Experimental
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Dexamethasone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Dexamethasone.Approved
Candesartan cilexetilThe serum concentration of Dexamethasone can be increased when it is combined with Candesartan.Approved
Capromab pendetideDexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Dexamethasone.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Dexamethasone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Dexamethasone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Dexamethasone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dexamethasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Dexamethasone.Approved, Investigational
CeritinibThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Dexamethasone.Withdrawn
ChloroquineThe serum concentration of Dexamethasone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideDexamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Dexamethasone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Dexamethasone can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexamethasone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone.Experimental
CilazaprilThe serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Dexamethasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Dexamethasone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Dexamethasone.Approved
ClemastineThe metabolism of Dexamethasone can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClofazimineThe serum concentration of Dexamethasone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
ClomipramineThe serum concentration of Dexamethasone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Dexamethasone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
ClotrimazoleThe metabolism of Dexamethasone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.Approved
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dexamethasone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Dexamethasone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Dexamethasone can be increased when it is combined with Conjugated estrogens.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Dexamethasone.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Dexamethasone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Dexamethasone.Investigational
CyclopenthiazideDexamethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Dexamethasone.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Dexamethasone.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dexamethasone.Approved
DabrafenibThe serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Dexamethasone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Dexamethasone.Approved
DaidzeinThe serum concentration of Dexamethasone can be increased when it is combined with Daidzein.Experimental
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Dexamethasone.Approved
DarunavirThe metabolism of Dexamethasone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dexamethasone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Dexamethasone.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dexamethasone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Dexamethasone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Dexamethasone.Investigational
DesipramineThe serum concentration of Dexamethasone can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dexamethasone.Approved
DesloratadineThe serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.Approved, Investigational
DextromethorphanThe serum concentration of Dexamethasone can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Dexamethasone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dexamethasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Dexamethasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Dexamethasone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dexamethasone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dexamethasone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Dexamethasone.Experimental
DihydroergotamineThe metabolism of Dexamethasone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Dexamethasone.Illicit
DiltiazemThe metabolism of Dexamethasone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Dexamethasone.Approved
DistigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Distigmine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Dexamethasone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dexamethasone.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DoxycyclineThe metabolism of Dexamethasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dexamethasone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Dexamethasone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Dexamethasone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dexamethasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dexamethasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Dexamethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dexamethasone.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Edrophonium.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Dexamethasone.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.Approved
EnalaprilThe serum concentration of Dexamethasone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Dexamethasone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Dexamethasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Dexamethasone can be increased when it is combined with Epimestrol.Experimental
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Dexamethasone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Dexamethasone.Approved
EquolThe serum concentration of Dexamethasone can be increased when it is combined with Equol.Investigational
ErgonovineThe serum concentration of Dexamethasone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Dexamethasone can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
ErythromycinThe metabolism of Dexamethasone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Dexamethasone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Dexamethasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.Approved
Etacrynic acidDexamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Dexamethasone.Experimental
Ethinyl EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Dexamethasone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Dexamethasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexamethasone.Approved, Investigational
EtravirineThe serum concentration of Dexamethasone can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Dexamethasone.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dexamethasone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Dexamethasone.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Dexamethasone.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Dexamethasone.Experimental
FelodipineThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexamethasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dexamethasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Dexamethasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Dexamethasone.Experimental
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Dexamethasone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Dexamethasone.Approved
FingolimodDexamethasone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Dexamethasone.Approved, Withdrawn
FluconazoleThe metabolism of Dexamethasone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Dexamethasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Dexamethasone.Experimental
FluoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneDexamethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Dexamethasone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Dexamethasone.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dexamethasone.Approved
FluvoxamineThe metabolism of Dexamethasone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone.Approved
FosaprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideDexamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Dexamethasone.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ginkgo biloba.Approved, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Dexamethasone.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Dexamethasone.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dexamethasone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.Approved
GLPG-0492Dexamethasone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe serum concentration of Dexamethasone can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Dexamethasone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Dexamethasone.Approved
Gramicidin DThe serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Dexamethasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Dexamethasone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Dexamethasone.Investigational
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.Approved
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Dexamethasone.Experimental
HexestrolThe serum concentration of Dexamethasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Dexamethasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.Approved, Investigational
HydrochlorothiazideDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
HydroflumethiazideDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Dexamethasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Dexamethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Dexamethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Dexamethasone.Approved
IdelalisibThe serum concentration of Dexamethasone can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Dexamethasone.Experimental
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Dexamethasone.Approved
IndapamideDexamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Dexamethasone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Dexamethasone.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexamethasone.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Dexamethasone.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dexamethasone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dexamethasone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Dexamethasone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ipidacrine.Experimental
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Dexamethasone.Approved, Investigational
IsavuconazoniumThe metabolism of Dexamethasone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dexamethasone.Withdrawn
IsradipineThe metabolism of Dexamethasone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dexamethasone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dexamethasone.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Dexamethasone.Experimental
KetamineThe serum concentration of Dexamethasone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dexamethasone.Approved
KetoconazoleThe metabolism of Dexamethasone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Dexamethasone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Dexamethasone.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dexamethasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.Approved, Investigational
LenalidomideDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Dexamethasone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.Approved
LevothyroxineThe serum concentration of Dexamethasone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Dexamethasone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone.Approved
LiothyronineThe serum concentration of Dexamethasone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dexamethasone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dexamethasone.Approved
LisinoprilThe serum concentration of Dexamethasone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexamethasone.Investigational
LomitapideThe serum concentration of Dexamethasone can be increased when it is combined with Lomitapide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Dexamethasone.Experimental
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Dexamethasone.Approved
LopinavirThe metabolism of Dexamethasone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Dexamethasone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.Approved
LovastatinThe metabolism of Dexamethasone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexamethasone.Approved
LuliconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dexamethasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Dexamethasone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Dexamethasone.Illicit, Withdrawn
MagaldrateThe bioavailability of Dexamethasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone.Approved
Magnesium silicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Dexamethasone.Approved, Investigational
MaprotilineThe serum concentration of Dexamethasone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone.Approved
MebendazoleThe serum concentration of Dexamethasone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexamethasone.Approved
MefloquineThe serum concentration of Dexamethasone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Dexamethasone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Dexamethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.Approved
MesteroloneDexamethasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Dexamethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Dexamethasone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Approved
MethadoneThe serum concentration of Dexamethasone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Dexamethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Methanesulfonyl Fluoride.Investigational
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Dexamethasone.Approved
MethyclothiazideDexamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dexamethasone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MethyltestosteroneDexamethasone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Dexamethasone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Dexamethasone.Experimental
MetoclopramideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Metoclopramide.Approved, Investigational
MetolazoneDexamethasone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Dexamethasone.Experimental
MibefradilThe serum concentration of Dexamethasone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit
MifepristoneThe serum concentration of Dexamethasone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Dexamethasone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
MitomycinThe serum concentration of Dexamethasone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Dexamethasone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Dexamethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Dexamethasone.Experimental
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.Approved, Investigational
MoxestrolThe serum concentration of Dexamethasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Dexamethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Dexamethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dexamethasone.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
NaltrexoneThe serum concentration of Dexamethasone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NandroloneDexamethasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexamethasone.Approved, Vet Approved
NaringeninThe serum concentration of Dexamethasone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
NefazodoneThe metabolism of Dexamethasone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dexamethasone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Dexamethasone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Dexamethasone.Approved
NetupitantThe serum concentration of Dexamethasone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dexamethasone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Dexamethasone.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Dexamethasone.Approved
NicorandilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Dexamethasone can be decreased when it is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Dexamethasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dexamethasone.Approved
NisoldipineThe serum concentration of Dexamethasone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Dexamethasone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Dexamethasone.Approved
NorethisteroneThe serum concentration of Dexamethasone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Norfloxacin.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Dexamethasone.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Dexamethasone.Approved, Investigational
OlaparibThe metabolism of Dexamethasone can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Dexamethasone.Experimental
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexamethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Dexamethasone.Approved
OmeprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Dexamethasone.Vet Approved
OsimertinibThe serum concentration of Dexamethasone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Dexamethasone.Approved
OxandroloneDexamethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Oxolinic acid.Experimental
OxymetholoneDexamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone.Withdrawn
P-NitrophenolThe serum concentration of Dexamethasone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone.Approved, Vet Approved
PalbociclibThe serum concentration of Dexamethasone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Dexamethasone.Approved, Investigational
PantoprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Pantoprazole.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Dexamethasone.Approved
ParoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Dexamethasone.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Dexamethasone can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Dexamethasone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dexamethasone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexamethasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Dexamethasone.Approved, Investigational
PhysostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Physostigmine.Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Dexamethasone.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.Approved, Investigational
PimozideThe serum concentration of Dexamethasone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pipemidic acid.Experimental
PiretanideDexamethasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Dexamethasone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Dexamethasone.Approved
Platelet Activating FactorThe serum concentration of Dexamethasone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Dexamethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDexamethasone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Dexamethasone.Approved
PosaconazoleThe metabolism of Dexamethasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dexamethasone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Dexamethasone.Experimental
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Dexamethasone.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PrimidoneThe serum concentration of Dexamethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dexamethasone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Dexamethasone.Experimental
PromestrieneThe serum concentration of Dexamethasone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexamethasone.Approved
PropafenoneThe serum concentration of Dexamethasone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Dexamethasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Dexamethasone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Dexamethasone.Experimental
ProtriptylineThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dexamethasone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Dexamethasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Dexamethasone can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.Approved
QuinacrineThe serum concentration of Dexamethasone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Dexamethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneDexamethasone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Dexamethasone.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Dexamethasone.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexamethasone.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Dexamethasone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dexamethasone.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Dexamethasone.Withdrawn
ReboxetineThe serum concentration of Dexamethasone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Dexamethasone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
ReserpineThe serum concentration of Dexamethasone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone.Experimental, Investigational
RifabutinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dexamethasone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational
RitonavirThe metabolism of Dexamethasone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Dexamethasone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Dexamethasone.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rosoxacin.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone.Approved
SaquinavirThe metabolism of Dexamethasone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone.Approved
ScopolamineThe serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Dexamethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Dexamethasone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dexamethasone.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Dexamethasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dexamethasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexamethasone.Investigational
SertralineThe serum concentration of Dexamethasone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Dexamethasone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.Approved
SiltuximabThe serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dexamethasone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Dexamethasone can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.Approved
SirolimusThe serum concentration of Dexamethasone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sitafloxacin.Experimental
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Dexamethasone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Dexamethasone.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Dexamethasone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sparfloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Dexamethasone.Experimental
SpironolactoneThe serum concentration of Dexamethasone can be increased when it is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Dexamethasone.Investigational
St. John's WortThe serum concentration of Dexamethasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololDexamethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Dexamethasone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dexamethasone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Dexamethasone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone.Approved
SulfinpyrazoneThe serum concentration of Dexamethasone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Dexamethasone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexamethasone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dexamethasone.Approved, Investigational
SumatriptanThe serum concentration of Dexamethasone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Dexamethasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Dexamethasone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Dexamethasone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Dexamethasone.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Dexamethasone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Dexamethasone.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dexamethasone.Withdrawn
TelithromycinThe metabolism of Dexamethasone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Dexamethasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexamethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Dexamethasone.Vet Approved
TerazosinThe serum concentration of Dexamethasone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Dexamethasone can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Dexamethasone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone.Approved
TesmilifeneThe serum concentration of Dexamethasone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Dexamethasone can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideDexamethasone may increase the dermatologic adverse activities of Thalidomide.Approved, Investigational, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone.Approved
TiboloneThe serum concentration of Dexamethasone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Dexamethasone can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Dexamethasone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dexamethasone.Investigational
TocilizumabThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDexamethasone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Dexamethasone.Approved
TorasemideDexamethasone may increase the hypokalemic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dexamethasone.Approved
TrazodoneThe serum concentration of Dexamethasone can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Dexamethasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideDexamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Dexamethasone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Dexamethasone can be increased when it is combined with Trimipramine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Dexamethasone.Withdrawn
TroleandomycinThe serum concentration of Dexamethasone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Dexamethasone.Experimental
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Dexamethasone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Dexamethasone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexamethasone.Investigational, Withdrawn
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Dexamethasone.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Dexamethasone.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Dexamethasone.Approved
VenlafaxineThe metabolism of Dexamethasone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Dexamethasone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Dexamethasone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.Approved, Investigational
VinorelbineThe serum concentration of Dexamethasone can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dexamethasone.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dexamethasone.Approved, Investigational
VoriconazoleThe metabolism of Dexamethasone can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Dexamethasone.Approved
WarfarinDexamethasone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone.Approved
ZeranolThe serum concentration of Dexamethasone can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dexamethasone.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Dexamethasone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Dexamethasone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dexamethasone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexamethasone.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.

References

Synthesis Reference

Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.

General References
Not Available
External Links
Human Metabolome Database
HMDB15364
KEGG Drug
D00292
KEGG Compound
C15643
PubChem Compound
5743
PubChem Substance
46508930
ChemSpider
5541
BindingDB
18207
ChEBI
41879
ChEMBL
CHEMBL384467
Therapeutic Targets Database
DAP000007
PharmGKB
PA449247
IUPHAR
2768
Guide to Pharmacology
GtP Drug Page
HET
DEX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Dexamethasone
ATC Codes
S03CA01 — Dexamethasone and antiinfectivesR01AD03 — DexamethasoneS02CA06 — Dexamethasone and antiinfectivesS01BA01 — DexamethasoneC05AA09 — DexamethasoneH02AB02 — DexamethasoneS01CB01 — DexamethasoneD10AA03 — DexamethasoneA01AC02 — DexamethasoneS02BA06 — DexamethasoneD07CB04 — Dexamethasone and antibioticsD07XB05 — DexamethasoneD07AB19 — DexamethasoneR01AD53 — Dexamethasone, combinationsS03BA01 — DexamethasoneS01CA01 — Dexamethasone and antiinfectives
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:04.04 — Antibacterials
  • 52:08.08 — Corticosteroids
PDB Entries
1m2z / 1p93 / 3gn8 / 3mne / 3mno / 3mnp / 4uda / 4udc
FDA label
Download (96 KB)
MSDS
Download (74.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0Active Not RecruitingBasic SciencePlasma Cell Myeloma1
0CompletedSupportive CareNausea / Vomiting1
0CompletedTreatmentImpacted Third Molar Tooth1
0CompletedTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
0Enrolling by InvitationPreventionDistal Radius Fractures / Synovitis of osteoarthritis1
0Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Non Hodgkin's Lymphoma / Pre B-Cell Acute Lymphoblastic Leukaemia1
0RecruitingBasic ScienceHealthy Volunteers1
0RecruitingTreatmentCesarean Section1
0RecruitingTreatmentOral Lichen Planus1
0TerminatedTreatmentMultiple Myeloma (MM)1
0TerminatedTreatmentRecurrent Cutaneous T-cell lymphoma / Refractory T-Cell Lymphoma / T-Cell Lymphomas1
1Active Not RecruitingDiagnosticHealthy Volunteers / Lean1
1Active Not RecruitingOtherMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAmyloidosis / Systemic Light Chain Amyloidosis1
1Active Not RecruitingTreatmentCholangiocellular Carcinoma) (ICC) / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
1Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
1Active Not RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentImpaired Renal Function / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute T-cell / Precursor T-Cell Lymphoblastic Lymphoma1
1Active Not RecruitingTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)7
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma4
1Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1Active Not RecruitingTreatmentRelapsed/Refractory Multiple Myeloma2
1CompletedNot AvailablePostoperative pain1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticCaudal Block1
1CompletedDiagnosticPulmonary Nodules1
1CompletedHealth Services ResearchCoarctation of the Aorta1
1CompletedPreventionLacrimation increased1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Lymphoid Leukemia Relapse / Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Malignancies / Cancer, Advanced1
1CompletedTreatmentAll / Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / Smith-Magenis Syndrome1
1CompletedTreatmentBronchiolitis1
1CompletedTreatmentCancers1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentColorectal Cancers / Metastatic Cancers1
1CompletedTreatmentEye Dryness1
1CompletedTreatmentGraves' Disease1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatic Insufficiency / Neoplasm Metastases1
1CompletedTreatmentHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukaemia, Acute / Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias2
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLymphoma, Low-Grade / Lymphoma, Mixed-Cell, Follicular / Lymphoma, Small Cleaved-Cell, Follicular / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentMalignancies / Neoplasms1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMesothelioma1
1CompletedTreatmentMultiple Myeloma (MM)14
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentNeoplasms / Neoplasms by Histologic Type / Neoplasms, Connective and Soft Tissue / Sarcomas / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentNon-infectious, Non-necrotizing Anterior Scleritis1
1CompletedTreatmentPain1
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1CompletedTreatmentTumors1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentVitrectomy therapy1
1CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
1Enrolling by InvitationTreatmentMyelodysplastic Syndromes1
1Not Yet RecruitingTreatmentAmyloid Light Chain (AL) Amyloidosis / Hematopoietic/Lymphoid Cancer1
1Not Yet RecruitingTreatmentHypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingOtherBlood Component Removal / Blood Donors / Granulocyte Colony-Stimulation Factor / Leukocyte Transfusion1
1RecruitingOtherMultiple Myeloma (MM)1
1RecruitingPreventionMigraines1
1RecruitingTreatmentAL Amyloidosis1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL)1
1RecruitingTreatmentAdnexal Masses / Borderline Ovarian Epithelial Tumor / Neoplasms, Ovarian / Ovarian Clear Cell Tumor / Ovarian Endometrioid Tumor / Ovarian Serous Tumor / Recurrent Ovarian Carcinoma1
1RecruitingTreatmentCancer, Breast / Prostate Cancer1
1RecruitingTreatmentCholangiocarcinomas / Neoplasms, Hepatic1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma / Multiple Myeloma (MM)1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentLeptomeningeal Metastases1
1RecruitingTreatmentLymphoid Hematological Malignancies / Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed and Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMultiple Myeloma (MM)10
1RecruitingTreatmentMultiple Myeloma (MM) / Relapsed and/or Refractory Multiple Myeloma1
1RecruitingTreatmentOsteoarthritis of the Knees1
1RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
1RecruitingTreatmentRetinoblastoma1
1RecruitingTreatmentStatus Asthmaticus1
1RecruitingTreatmentTraumas1
1RecruitingTreatmentTumors, Solid1
1SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1SuspendedTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Central Nervous System Lymphoma / Intraocular Lymphoma / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Recurrent Adult Diffuse Large Cell Lymphoma / Retinal Lymphoma1
1SuspendedTreatmentCongestive Heart Failure (CHF)1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1SuspendedTreatmentMultiple Myeloma (MM)1
1SuspendedTreatmentRecurrent Plasma Cell Myeloma1
1TerminatedTreatmentAcute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood Infratentorial Ependymoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Gonadotroph Adenoma / Pituitary Basophilic Adenoma / Pituitary Chromophobe Adenoma / Pituitary Eosinophilic Adenoma / Prolactin Secreting Adenoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Pituitary Tumor / Recurrent/Refractory Childhood Hodgkin Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / TSH Secreting Adenoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentLeukemias1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1TerminatedTreatmentMultiple Myeloma (MM)3
1TerminatedTreatmentPlasma Cell Myeloma2
1TerminatedTreatmentRecurrent Childhood Anaplastic Astrocytoma / Recurrent Childhood Anaplastic Oligoastrocytoma / Recurrent Childhood Anaplastic Oligodendroglioma / Recurrent Childhood Giant Cell Glioblastoma / Recurrent Childhood Glioblastoma / Recurrent Childhood Gliomatosis Cerebri / Recurrent Childhood Gliosarcoma1
1TerminatedTreatmentRotator Cuff Syndrome1
1TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
1Unknown StatusTreatmentLateral Epicondylitis (Tennis Elbow)1
1WithdrawnTreatmentMalignant Lymphomas1
1WithdrawnTreatmentMalignant Lymphomas / Neoplasms, Brain / Sarcoma, Osteogenic / Sarcomas / Wilms' tumor1
1WithdrawnTreatmentMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Multiple Myeloma (MM)1
1WithdrawnTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentAL Amyloidosis1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentCancer, Ovarian / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Lymphomas / Multiple Myeloma (MM) / Renal Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Tiredness / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentEsophageal Cancers1
1, 2Active Not RecruitingTreatmentIndolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)24
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma2
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma3
1, 2Active Not RecruitingTreatmentRelapsed and/or Relapsed-refractory Multiple Myeloma1
1, 2CompletedSupportive CareNeovascular Age-Related Macular Degeneration1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentBranch Retinal Vein Occlusion / Macular Degeneration / Macular Edema (ME)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentDiabetic Macular Edema (DME)1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMultiple Myeloma (MM)5
1, 2CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentPatients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal1
1, 2CompletedTreatmentPlasma Cell Myeloma2
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2Not Yet RecruitingTreatmentAmyloidosis1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Not Yet RecruitingTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed/Refractory Multiple Myeloma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAmyloidosis / Plasma Cell Myeloma1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma1
1, 2RecruitingTreatmentGeneral Surgery / Pelvic Organ Prolapse (POP) / Postoperative pain1
1, 2RecruitingTreatmentHaematological Malignancies1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentLoss of Chromosome 17p / Recurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMigraines1
1, 2RecruitingTreatmentMultiple Myeloma (MM)15
1, 2RecruitingTreatmentPlasma Cell Myeloma2
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentT-cell Acute Lymphoblastic Leukemia / T-cell Lymphoblastic Lymphoma1
1, 2RecruitingTreatmentTreatments1
1, 2SuspendedTreatmentMultiple Myeloma (MM)1
1, 2SuspendedTreatmentMultiple Myeloma in Relapse1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentMacular Edema (ME)1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Unknown StatusPreventionTonsillectomy1
1, 2Unknown StatusTreatmentAmyloidosis1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)4
1, 2Unknown StatusTreatmentSwallowing1
1, 2WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentMelanoma1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)3
2Active Not RecruitingTreatmentAL Amyloidosis1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2Active Not RecruitingTreatmentAdvanced Cancers / Haematological disorders / Tumors, Solid1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAmyloidosis1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / Lymphoma, Mantle-Cell / MALT Lymphoma / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentLabour1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentLiver Cancer1
2Active Not RecruitingTreatmentLung Cancers / Neoplasms Metastasis1
2Active Not RecruitingTreatmentLymphoma, Hodgkins1
2Active Not RecruitingTreatmentMalignant Lymphomas2
2Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)31
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Relapse After Use of Lenalidomide and Bortezomib1
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Renal Failure1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurotoxicity1
2Active Not RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma, Refractory1
2Active Not RecruitingTreatmentNasal Type Extranodal NK/T-Cell Lymphoma1
2Active Not RecruitingTreatmentNeoplasms Metastasis1
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentPlasma Cell Myeloma2
2Active Not RecruitingTreatmentPrimary Amyloidosis of Light Chain Type1
2Active Not RecruitingTreatmentPrior Bortezomib Therapy Acceptable / Waldenstroms1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Myeloma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma3
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2Active Not RecruitingTreatmentT-Cell Lymphomas1
2Active Not RecruitingTreatmentTumors, Solid1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedPreventionCINV1
2CompletedPreventionCancers1
2CompletedPreventionDiabetes / Macular Edema (ME) / Pseudophakia1
2CompletedPreventionEffects of; Anesthesia, in Labor and Delivery1
2CompletedPreventionNausea and Vomiting, Postoperative1
2CompletedPreventionPostspinal Shivering1
2CompletedPreventionSuspected Appendicitis1
2CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedSupportive CareColorectal Cancers / Nausea and Vomiting1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas1
2CompletedSupportive CareMalignant Lymphomas / Myeloma, Plasma-Cell1
2CompletedSupportive CareNausea / Vomiting1
2CompletedSupportive CarePain1
2CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentAcute Anterior Uveitis1
2CompletedTreatmentAcute Gouty Arthritis1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Hepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdrenal Hyperplasia, Congenital1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentAge Related Macular Degeneration (ARMD)1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAnterior Uveitis (AU)1
2CompletedTreatmentBlast Crisis / Leukemia, Lymphocytic, Acute / Leukemia,Myeloid, Chronic / Philadelphia Chromosome1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancer, Ovarian / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentCataracts1
2CompletedTreatmentChemotherapy-Induced / Nausea and Vomiting1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers1
2CompletedTreatmentConjunctivitis, Seasonal Allergic2
2CompletedTreatmentContiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Marginal Zone Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentDiabetic Macular Edema (DME)2
2CompletedTreatmentDiabetic Macular Edema (DME) / Vitrectomy therapy1
2CompletedTreatmentDisease, Adnexal / Endocrine Gland Neoplasms / Genital Diseases, Female / Neoplasms / Neoplasms by Site / Neoplasms, Ovarian / Ovarian Diseases1
2CompletedTreatmentDry Eye Syndrome (DES)1
2CompletedTreatmentEar Diseases / Otitis / Otitis Externa / Otorhinolaryngologic Diseases1
2CompletedTreatmentEmpyema / Parapneumonic Pleural Effusion1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentGenetic Syndrome / Nervous System Disorders1
2CompletedTreatmentGenital Neoplasms, Female Urogenital Neoplasms / Neoplasms, Endometrial / Uterine Neoplasms1
2CompletedTreatmentGlomerulonephritis / Glomerulonephritis minimal lesion1
2CompletedTreatmentHard of Hearing1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHematologic Cancers1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentImmune Thrombocytopenia1
2CompletedTreatmentImmune Thrombocytopenic Purpura ( ITP )2
2CompletedTreatmentLeiomyosarcomas / Liposarcoma1
2CompletedTreatmentLeukemia, Lymphocytic, Acute1
2CompletedTreatmentLeukemias10
2CompletedTreatmentLeukemias / Malignant Lymphomas4
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentMacular Degeneration / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentMacular Edema (ME)1
2CompletedTreatmentMacular Edema (ME) / Retinopathy, Diabetic1
2CompletedTreatmentMacular Edema After Cataract Surgery in Patients With Diabetes Mellitus1
2CompletedTreatmentMaculopathies, Age-Related / Subfoveal Choroidal Neovascularization2
2CompletedTreatmentMalignant Lymphomas18
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2CompletedTreatmentMultiple Myeloma (MM)37
2CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm17
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentMyxoid Liposarcoma1
2CompletedTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentOral Chronic Graft-Versus-Host Disease1
2CompletedTreatmentOral Lichen Planus1
2CompletedTreatmentPOEMS Syndrome2
2CompletedTreatmentPemphigus1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentPrimary Plasma Cell Leukemia1
2CompletedTreatmentPrimary Systemic Amyloidosis2
2CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentSj(SqrRoot)(Delta)Gren s Syndrome / Xerostomia1
2CompletedTreatmentSpinal Cord Compression From Neoplasm Metastasis1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentWaldenstrom's Macroglobulinemia (WM)2
2CompletedTreatmentWaldenstroms Macroglobulinemia1
2CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting2
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingSupportive CareCaudal Block1
2Not Yet RecruitingSupportive CareLung Cancers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Not Yet RecruitingTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2Not Yet RecruitingTreatmentBronchiolitis1
2Not Yet RecruitingTreatmentChronic Subdural Hematomas1
2Not Yet RecruitingTreatmentFocus of Study / Thrombocytopenias1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentLichen Planus (LP)1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)3
2Not Yet RecruitingTreatmentMultiple Myeloma in Relapse1
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentOvarian Hyperstimulation Syndrome1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma2
2Not Yet RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2Not Yet RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2Not Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingPreventionPostoperative pain1
2RecruitingSupportive CareAdvanced Cancers1
2RecruitingSupportive CareMultiple Myeloma (MM)2
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAnterior chamber inflammation / Cataracts / Postoperative pain1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBladder Cancers / Urothelial Cancer1
2RecruitingTreatmentCardiac Amyloidosis1
2RecruitingTreatmentCholangiocellular Carcinoma / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
2RecruitingTreatmentChronic Kidney Disease (CKD) / Multiple Myeloma (MM)1
2RecruitingTreatmentChronic Limb Ischemia2
2RecruitingTreatmentChronic Lung Disease of Prematurity1
2RecruitingTreatmentColorectal Adenocarcinoma Metastatic to the Liver1
2RecruitingTreatmentDiabetes / Diabetic Macular Edema (DME) / Retinopathy, Diabetic1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentExtranodal NK-T-CELL LYMPHOMA / NK/T Cell Lymphoma1
2RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentHead and Neck Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentHeavy Menstrual Bleeding1
2RecruitingTreatmentHematopoietic/Lymphoid Cancer / Richter's Transformation1
2RecruitingTreatmentHenoch-Schoenlein Purpura (HSP)1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentImmune Thrombocytopenia2
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentLeukemias7
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentLymphoma, Lymphoblastic1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2RecruitingTreatmentMultiple Myeloma (MM)35
2RecruitingTreatmentMultiple Myeloma (MM) / Relapsed/Refractory1
2RecruitingTreatmentMultiple Myeloma in Relapse1
2RecruitingTreatmentPOEMS Syndrome1
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPlasma Cell Myeloma3
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentProphylaxis against postoperative nausea and vomiting / Vomiting1
2RecruitingTreatmentPulmonary Fibrosis1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma2
2RecruitingTreatmentRecurrent Primary Amyloidosis1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma3
2RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)2
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentSudden Sensorineural Hearing Loss (SSNHL)1
2RecruitingTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2RecruitingTreatmentWet Macular Degeneration1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentMalignant Lymphomas1
2TerminatedPreventionNausea / Vomiting1
2TerminatedSupportive CareBrain Cancer1
2TerminatedSupportive CareNausea and Vomiting / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2TerminatedSupportive CareNausea / Unspecified Childhood Solid Tumor, Protocol Specific / Vomiting1
2TerminatedTreatmentAcute Adenoviral Conjunctivitis1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAcute Otitis Media1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast / Lung Cancers1
2TerminatedTreatmentCancers / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCorneal Infiltrates1
2TerminatedTreatmentCystoid Macular Edema / Macular Edema (ME) / Radiation Maculopathy / Radiation Retinopathy / Uveal Melanoma1
2TerminatedTreatmentFollicular Lymphoma (FL)1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemias2
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMaculopathies, Age-Related / Subfoveal Choroidal Neovascularization1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMantle Cell Lymphoma (MCL)1
2TerminatedTreatmentMultiple Myeloma (MM)8
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2TerminatedTreatmentProstate Cancer3
2TerminatedTreatmentRadiculopathy, Cervical1
2TerminatedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentRefractory Multiple Myeloma2
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentSurgery, Hand1
2Unknown StatusPreventionAirway Obstruction2
2Unknown StatusPreventionProliferative Diabetic Retinopathy (PDR)1
2Unknown StatusPreventionProphylaxis against postoperative nausea and vomiting / Tumors, Solid1
2Unknown StatusSupportive CareNausea / Vomiting1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentDiabetic Macular Edema (DME) / Non-Proliferative Diabetic Retinopathy / Proliferative Diabetic Retinopathy (PDR)1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMalignant / Mesothelioma / Pleural1
2Unknown StatusTreatmentMultiple Myeloma (MM)7
2Unknown StatusTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentPOEMS Syndrome1
2Unknown StatusTreatmentPostoperative pain / Postoperative Vocal Function / Prophylaxis against postoperative nausea and vomiting / Thyroidectomy1
2Unknown StatusTreatmentRectal Carcinoma1
2Unknown StatusTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Unknown StatusTreatmentWaldenstrom's Macroglobulinemia (WM)1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentAge Related Macular Degeneration (ARMD)1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCancer, Breast1
2WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
2WithdrawnTreatmentImmune Thrombocytopenia1
2WithdrawnTreatmentMalignant Lymphomas4
2WithdrawnTreatmentMultiple Myeloma (MM)9
2WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentPatients With Acute Pancreatitis1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRenal Cell Adenocarcinoma1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3Active Not RecruitingPreventionAdjuvants, Anesthesia1
2, 3Active Not RecruitingTreatmentImmune Thrombocytopenia / Pregnancy1
2, 3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentCellophane Maculopathy / Epiretinal Membrane / Macular Edema (ME) / Retinal Edema1
2, 3CompletedTreatmentMultiple Myeloma (MM)2
2, 3CompletedTreatmentNon-Ischemic Central Retinal Vein Occlusion1
2, 3CompletedTreatmentPemphigus1
2, 3CompletedTreatmentPlantar fascial fibromatosis1
2, 3CompletedTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedTreatmentTuberculous Meningitis1
2, 3CompletedTreatmentDiffuse posterior uveitis / Uveitis, Intermediate1
2, 3RecruitingSupportive CareSynovitis of osteoarthritis / Total Hip Arthroplasty (THA) / Total Knee Arthroplasty (TKA)1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentChronic Subdural Hematomas2
2, 3RecruitingTreatmentHepatectomy / Hyperbilirubinemia / Jaundice / Liver Dysfunction1
2, 3RecruitingTreatmentLeukemias2
2, 3RecruitingTreatmentLymphoma, Lymphoblastic1
2, 3RecruitingTreatmentMultiple Myeloma (MM)1
2, 3RecruitingTreatmentNeurocysticercosis1
2, 3RecruitingTreatmentPost Surgical Pain1
2, 3RecruitingTreatmentPremature Births1
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2, 3TerminatedPreventionShoulder Surgery1
2, 3TerminatedTreatmentAnterior Uveitis (AU)1
2, 3TerminatedTreatmentLeptospirosis1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
2, 3Unknown StatusTreatmentLeukemias1
2, 3WithdrawnTreatmentHIV-infection/Aids / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3Active Not RecruitingBasic ScienceNewly Diagnosed, Previously Untreated Multiple Myeloma1
3Active Not RecruitingPreventionDysphasia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentIdiopathic Thrombocytopenic Purpura (ITP)1
3Active Not RecruitingTreatmentLeukemias3
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3Active Not RecruitingTreatmentLymphoma (Myeloma) / Malignant Lymphomas / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentMalignant Lymphomas3
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)16
3Active Not RecruitingTreatmentProstate Cancer1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
3CompletedNot AvailableAcute Otitis Media1
3CompletedNot AvailablePneumonia1
3CompletedDiagnosticDevelopment1
3CompletedDiagnosticPolycystic Ovarian Syndrome1
3CompletedPreventionCataracts / Cystoid Macular Edema / Diabetes Mellitus (DM)1
3CompletedPreventionChronic Lung Diseases / Respiratory Distress Syndrome (RDS)1
3CompletedPreventionDiabetic Macular Edema (DME)1
3CompletedPreventionHernia, Femoral / Inguinal Hernias1
3CompletedPreventionInfection, Postoperative Wound / Surgery, Colon1
3CompletedPreventionNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedPreventionNeoplasms1
3CompletedPreventionPelvic Organ Prolapse (POP) / Ponv1
3CompletedPreventionPostoperative Fatigue / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
3CompletedPreventionThyroid Diseases / Thyroidectomy1
3CompletedPreventionVomiting1
3CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting11
3CompletedSupportive CareAnemias / Prostate Cancer / Tiredness1
3CompletedSupportive CareBone Metastases1
3CompletedSupportive CareCancers1
3CompletedSupportive CareGenital Neoplasms, Female / Nausea / Vomiting1
3CompletedSupportive CareNausea1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific3
3CompletedSupportive CareNausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting1
3CompletedSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3CompletedTreatmentAcute Otitis Externa2
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentAnaesthesia therapy / Forearm Injuries / Postoperative pain1
3CompletedTreatmentAnterior Uveitis (AU)1
3CompletedTreatmentBlepharoconjunctivitis1
3CompletedTreatmentBone Metastases1
3CompletedTreatmentBronchiolitis1
3CompletedTreatmentCancer, Ovarian1
3CompletedTreatmentCancers / Nausea / Vomiting1
3CompletedTreatmentCarcinoma NOS / Non Small Cell Lung1
3CompletedTreatmentCataracts2
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChronic Allergic Conjunctivitis1
3CompletedTreatmentChronic Lung Disease of Prematurity1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentBacterial blepharitis / Conjunctivitis / Corneal Inflammation2
3CompletedTreatmentDiabetic Macular Edema (DME)2
3CompletedTreatmentEye Dryness1
3CompletedTreatmentFocal Lipoid Glomerulosclerosis / Nephrosis1
3CompletedTreatmentGlomerulosclerosis, Focal Segmental1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Oral Manifestations1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP)2
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura1
3CompletedTreatmentImmune Thrombocytopenia1
3CompletedTreatmentInfection NOS / Neutropenias1
3CompletedTreatmentInteraction Between Antiemetic Drugs and Paracetamol1
3CompletedTreatmentKnee Injuries1
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias12
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentLung Cancers / Metastatic Cancers1
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentM-Protein / Multiple Myeloma (MM) / Myeloma Proteins / Plasma Cell Myeloma1
3CompletedTreatmentMacular Edema (ME)1
3CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)2
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentMigraines2
3CompletedTreatmentMultiple Myeloma (MM)21
3CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Renal Failure1
3CompletedTreatmentMultiple Myeloma de Novo Treatment1
3CompletedTreatmentNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedTreatmentNeurocysticercosis1
3CompletedTreatmentNonneoplastic Condition1
3CompletedTreatmentOcular Inflammation Associated With Blepharaconjunctivitis1
3CompletedTreatmentPain Management After Surgery1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPost Ocular Surgical Inflammation and Pain2
3CompletedTreatmentPost Ocular Surgical Inflammation and Pain / Post-Surgical Ocular Inflammation / Post-Surgical Ocular Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentPrimary Systemic Amyloidosis (AL)1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
3CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
3CompletedTreatmentRespiratory Distress Syndrome (RDS)1
3CompletedTreatmentRotator Cuff Syndrome / Shoulder Bursitis1
3CompletedTreatmentUpper Extremity Fractures1
3CompletedTreatmentBacterial blepharitis2
3CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting2
3Not Yet RecruitingOtherAsthma Bronchial1
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3Not Yet RecruitingPreventionOvarian Hyperstimulation Syndrome1
3Not Yet RecruitingSupportive CareColorectal Cancers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
3Not Yet RecruitingSupportive CarePostoperative pain1
3Not Yet RecruitingSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting2
3Not Yet RecruitingTreatmentAmyloidosis1
3Not Yet RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Not Yet RecruitingTreatmentDrug-Induced Liver Injury / Tuberculosis / Tuberculous Meningitis1
3Not Yet RecruitingTreatmentGlaucoma1
3Not Yet RecruitingTreatmentHSV Encephalitis1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic1
3Not Yet RecruitingTreatmentMajor Non-cardiac Surgery1
3Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentObstetric Pain / Other Complications of Obstetric Anesthesia - Delivered1
3Not Yet RecruitingTreatmentPlasma Cell Myeloma1
3Not Yet RecruitingTreatmentPlasmacytoma1
3RecruitingPreventionAcute Urinary Tract Infection / Urinary Tract Infections (UTIs)1
3RecruitingPreventionChildhood Cancers / Nausea / Vomiting1
3RecruitingPreventionPain1
3RecruitingPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
3RecruitingSupportive CareBrachial Plexus Block1
3RecruitingSupportive CareMalignant Neoplasms of Male Genital Organs1
3RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAnesthesia, Conduction1
3RecruitingTreatmentAnterior Uveitis (AU)1
3RecruitingTreatmentAsthma Bronchial2
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentCardiopulmonary Bypass / Defect, Congenital Heart / Surgery, Cardiac1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentAcute nonspecific tenosynovitis / DeQuervain's Tenosynovitis / Inflammatory Diseases / Lateral Epicondylitis / Trigger Finger1
3RecruitingTreatmentDrug-Induced Liver Injury / Human Immunodeficiency Virus (HIV) / IRIS / Tuberculosis / Tuberculous Meningitis1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal Type1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type1
3RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
3RecruitingTreatmentHeadaches / Intranasal Ketamine1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentInflammatory Macular Edema1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3RecruitingTreatmentMacular Edema (ME)1
3RecruitingTreatmentMacular Edema (ME) / Uveitis1
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentMultiple Myeloma (MM)18
3RecruitingTreatmentNeuroblastomas / Opsoclonus Myoclonus Syndrome1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentPain1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentPlasma Cell Myeloma1
3RecruitingTreatmentPostoperative pain1
3RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
3RecruitingTreatmentPurpura, Thrombocytopenic, Idiopathic1
3RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
3RecruitingTreatmentRelapsed and Refractory Multiple Myeloma1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
3RecruitingTreatmentSoft Tissue Sarcoma (STS)1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
3RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentMultiple Myeloma (MM)2
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
3TerminatedSupportive CareHeadaches / Vomiting1
3TerminatedTreatmentAcute Fungal Otitis Externa1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentAcute Otitis Externa1
3TerminatedTreatmentChronic Lung Disease of Prematurity / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Respiratory Distress Syndrome (RDS)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentDysphagia After Anterior Cervical Decompression and Fusion of the Spine1
3TerminatedTreatmentLiver Cirrhosis1
3TerminatedTreatmentMalignant Lymphomas2
3TerminatedTreatmentMultiple Myeloma (MM)5
3TerminatedTreatmentOtitis Externa1
3TerminatedTreatmentOtitis Media in Patients With Tympanostomy Tubes1
3TerminatedTreatmentProstate Cancer1
3TerminatedTreatmentSickle Cell Disorders1
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3TerminatedTreatmentVomiting2
3Unknown StatusPreventionDrug hypersensitivity reaction1
3Unknown StatusPreventionNausea / Vomiting1
3Unknown StatusPreventionRespiratory; Disorder, Functional, Impaired1
3Unknown StatusTreatmentAcute Bacterial Conjunctivitis1
3Unknown StatusTreatmentAcute Otitis Externa1
3Unknown StatusTreatmentAcute / Conjunctivitis, Bacterial1
3Unknown StatusTreatmentAllergies / Skin Inflammation1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Fungal Vaginal Infections1
3Unknown StatusTreatmentExtramedullary Plasmacytoma1
3Unknown StatusTreatmentHELLP Syndrome1
3Unknown StatusTreatmentLeukemias2
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)1
3Unknown StatusTreatmentMalignant Lymphomas7
3Unknown StatusTreatmentMultiple Myeloma (MM)4
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentOral Lichen Planus1
3Unknown StatusTreatmentPost-Operative Pain1
3Unknown StatusTreatmentSarcoidosis1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3Unknown StatusTreatmentNeurocostal neuralgia1
3WithdrawnSupportive CareCancers / Nausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting / Solid Tumor Cancers1
3WithdrawnTreatmentBlepharoconjunctivitis1
3WithdrawnTreatmentDisorder of Rotator Cuff / Disorder of Shoulder / Disorder of Tendon of Biceps / Injury of Shoulder Region / Shoulder Pain1
3WithdrawnTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura2
3WithdrawnTreatmentMultiple Myeloma (MM)1
3WithdrawnTreatmentPost-surgical Inflammation1
3WithdrawnTreatmentSkin Inflammation1
4Active Not RecruitingPreventionPostoperative Cognitive Dysfunction1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4Active Not RecruitingTreatmentDisorder of Shoulder / Postoperative pain1
4Active Not RecruitingTreatmentHELLP Syndrome1
4Active Not RecruitingTreatmentMedical Induction of Labor Affecting Fetus1
4Active Not RecruitingTreatmentModified Radical Mastectomy1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)3
4Active Not RecruitingTreatmentOpen-angle Glaucoma (OAG)1
4Active Not RecruitingTreatmentPeripheral Arterial Disease (PAD)1
4Active Not RecruitingTreatmentVomiting2
4CompletedNot AvailablePostoperative pain1
4CompletedBasic ScienceCancer, Ovarian1
4CompletedBasic SciencePremature Births1
4CompletedDiagnosticConjunctivitis, Seasonal Allergic1
4CompletedHealth Services ResearchBronchiolitis1
4CompletedPreventionAcute Leukemic Patients in Children1
4CompletedPreventionArthrosis, Unspecified, Ankle and Foot1
4CompletedPreventionChronic Obstructive Pulmonary Disease (COPD)2
4CompletedPreventionCisplatin Ototoxicity1
4CompletedPreventionEdema1
4CompletedPreventionFoot and Ankle Procedures1
4CompletedPreventionMigraines1
4CompletedPreventionNausea / Neoplasms / Vomiting1
4CompletedPreventionNausea / Postoperative Nausea and Vomiting (PONV)1
4CompletedPreventionNausea / Vomiting1
4CompletedPreventionPain Measurement1
4CompletedPreventionPain / Throat Pain1
4CompletedPreventionPostoperative Cognitive Dysfunction1
4CompletedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting8
4CompletedPreventionThroat Pain1
4CompletedPreventionVomiting1
4CompletedSupportive CareFracture, Ankle1
4CompletedSupportive CareInterscalene Blockade in Elective Arthroscopic Rotator Cuff Repair / Shoulder Injury1
4CompletedSupportive CarePonv1
4CompletedSupportive CarePostoperative pain1
4CompletedTreatmentAbdominal Surgeries / Analgesia, Patient-Controlled / Analgesia, Postoperative / Postoperative pain1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction / Regional Anesthesia, Saphenous Nerve Block1
4CompletedTreatmentArthritis / Shoulder Impingement Syndrome1
4CompletedTreatmentAsthma Bronchial / Reactive Airways Disease (RAD)1
4CompletedTreatmentAtypical Facial Pain / Typical Facial Pain1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCataracts / Cystoid Macular Edema Following Cataract Surgery / Diabetic Macular Edema (DME) / Macular Edema, Cystoid / Vision Disorders1
4CompletedTreatmentCroup1
4CompletedTreatmentDiabetic Macular Edema (DME)2
4CompletedTreatmentDiabetic Macular Edema (DME) / Epiretinal Membrane1
4CompletedTreatmentEpithelial Defect After Phototherapeutic Keratectomy1
4CompletedTreatmentIncomplete Reversal of Neuromuscular Block1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentIntraocular Pressure1
4CompletedTreatmentLocal Anesthesia1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)2
4CompletedTreatmentMacular Edema (ME) / Uveitis1
4CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNasal Surgery1
4CompletedTreatmentNausea / Vomiting1
4CompletedTreatmentNonvalvular Atrial Fibrillation / Surgery, Cardiac1
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedTreatmentOsteoarthritis of the Knees2
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPTSD1
4CompletedTreatmentPain1
4CompletedTreatmentPain, Acute / Pain, Chronic1
4CompletedTreatmentPain / Peripheral Nerve Blocks1
4CompletedTreatmentPain / Postoperative1
4CompletedTreatmentPain / Shoulder Arthroscopy1
4CompletedTreatmentPostoperative Complications1
4CompletedTreatmentPostoperative Sore Throat, Cough, Hoarseness1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
4CompletedTreatmentRecession, Gingival1
4CompletedTreatmentRetinal Vein Occlusions(RVO)1
4CompletedTreatmentRupture of Anterior Cruciate Ligament1
4CompletedTreatmentSjögren's Syndrome1
4CompletedTreatmentTotal Knee Arthroplasty (TKA)1
4CompletedTreatmentVernal Keratoconjunctivitis1
4CompletedTreatmentViral Bronchiolitis1
4CompletedTreatmentSynovitis of osteoarthritis1
4Enrolling by InvitationTreatmentSacro-Iliac Spondylosis1
4Not Yet RecruitingBasic ScienceInsulin Secretion1
4Not Yet RecruitingPreventionDelirium / Dexamethasone / Flubiprofen Axetil / Lung Cancer Non-Small Cell Cancer (NSCLC) / Surgery--Complications1
4Not Yet RecruitingPreventionPostoperative pain1
4Not Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingSupportive CareDexamethasone / Flubiprofen Axetil / General Surgery / Long-Term Effects Secondary to Cancer Therapy in Adults / Lung Cancer Non-Small Cell Cancer (NSCLC)1
4Not Yet RecruitingTreatmentAddison's Disease1
4Not Yet RecruitingTreatmentArthroplasty, Knee Replacement / Postoperative pain1
4Not Yet RecruitingTreatmentCancers / Nausea / Vomiting1
4Not Yet RecruitingTreatmentDiabetic Macular Edema (DME)1
4Not Yet RecruitingTreatmentInflammatory Responses1
4Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
4Not Yet RecruitingTreatmentOtitis Media (OM) / Otorrhoea1
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentRadiculopathy, Cervical1
4Not Yet RecruitingTreatmentTuberculous Meningitis1
4Not Yet RecruitingTreatmentPh+ Acute Lymphoblastic Leukemia1
4RecruitingNot AvailableLung Cancers1
4RecruitingBasic ScienceCritical Limb Ischemia (CLI) / Peripheral Artery Disease (PAD) / Vascular Diseases1
4RecruitingBasic ScienceStress1
4RecruitingOtherPain / Shoulder Arthroscopy1
4RecruitingPreventionAnesthesia, Pediatrics, Surgery1
4RecruitingPreventionDelirium / Postoperative Cognitive Dysfunction1
4RecruitingPreventionFractures, Bone / Morphine Adverse Reaction / Nausea and Vomiting, Postoperative / Pruritus / Satisfaction, Personal1
4RecruitingPreventionKeloid Scars1
4RecruitingPreventionMigraines1
4RecruitingPreventionNeuritis / Radioiodine ablation of thyroid tissue1
4RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4RecruitingSupportive CareCancers / Tumors1
4RecruitingTreatmentAbdominal Pain (AP) / Nausea1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)2
4RecruitingTreatmentAmbulatory Surgical Procedures / Brachial Plexus Block / Postoperative pain / Shoulder Joint Disorder1
4RecruitingTreatmentAnterior Cruciate Ligament Injury1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentCancers1
4RecruitingTreatmentCentral Retinal Vein Occlusion (CRVO) / Macular Edema (ME)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentDexamethasone / Supraclavicular Brachial Plexus Block1
4RecruitingTreatmentDiabetes Mellitus (DM) / Macular Edema (ME) / Retinal Exudates and Deposits1
4RecruitingTreatmentDiabetic Macular Edema (DME)2
4RecruitingTreatmentHeadaches1
4RecruitingTreatmentImmune Thrombocytopenia1
4RecruitingTreatmentInflammatory Reaction / Intraocular Pressure1
4RecruitingTreatmentInflammatory Reaction / Postoperative pain / Synovitis of osteoarthritis1
4RecruitingTreatmentKidney Diseases / Postoperative Complications1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentMyofascial Pain Syndrome1
4RecruitingTreatmentOsteoarthritis of the Knees1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPain, Radiating1
4RecruitingTreatmentPediatric Post-tonsillectomy Pain1
4RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentCaudal epidural block therapy / Shoulder Surgery1
4SuspendedTreatmentMacular Edema (ME) / Uveitis1
4TerminatedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4TerminatedTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4TerminatedTreatmentGeneral Surgery1
4TerminatedTreatmentHematoma, Subdural, Chronic1
4TerminatedTreatmentHip Fractures1
4TerminatedTreatmentPain1
4TerminatedTreatmentPostoperative pain2
4TerminatedTreatmentTrigger Finger Disorder1
4TerminatedTreatmentTumors1
4Unknown StatusTreatmentAcute Bronchiolitis1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentArthritis1
4Unknown StatusTreatmentChronic Rhinosinusitis1
4Unknown StatusTreatmentDexamethasone / Interscalene Block / Low Volume Regional Anesthesia / Shoulder Arthroscopy1
4Unknown StatusTreatmentDuration of Pain Relief1
4Unknown StatusTreatmentFracture of Neck of Femur1
4Unknown StatusTreatmentInfertilities1
4Unknown StatusTreatmentPost Minimally Invasive Thorascopic Surgical Pain1
4Unknown StatusTreatmentPostoperative pain1
4WithdrawnNot AvailableAdrenal Insufficiency1
4WithdrawnSupportive CareRetinal Detachment1
4WithdrawnTreatmentAnalgesia Duration1
4WithdrawnTreatmentImmune Thrombocytopenia1
4WithdrawnTreatmentNeuromuscular Blockade1
4WithdrawnTreatmentPain / Total Knee Arthroplasty (TKA)1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingPreventionSwallowing Disorders1
Not AvailableActive Not RecruitingSupportive CarePain / Recurrent Oropharyngeal Squamous Cell Carcinoma / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Swallowing Disorders1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentCervical Spine1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableApproved for MarketingNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)2
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableAdenotonsillectomy / Tonsillectomy1
Not AvailableCompletedNot AvailableAmyloidosis1
Not AvailableCompletedNot AvailableDiabetic Macular Edema (DME)1
Not AvailableCompletedNot AvailableGlucose tolerance impaired / Insulin Resistance1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableMacular Edema (ME)3
Not AvailableCompletedNot AvailableMacular Edema (ME) / Retinal Vein Occlusions(RVO)3
Not AvailableCompletedNot AvailableDiffuse posterior uveitis / Macular Edema (ME) / Retinal Vein Occlusions(RVO)1
Not AvailableCompletedNot AvailableMacular Edema (ME) / Visual Acuity1
Not AvailableCompletedNot AvailableMacular Oedema / Retinal Vein Occlusions(RVO)1
Not AvailableCompletedNot AvailableNeuromuscular Blockade1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailablePost-operative Swallowing Disorders / Thyroidectomy1
Not AvailableCompletedNot AvailableRetinal Vein Occlusions(RVO)1
Not AvailableCompletedBasic ScienceAnterior Uveitis (AU) / Iridocyclitis / Iritis / Macular Edema (ME) / Uveitis1
Not AvailableCompletedBasic ScienceExperimental Lung Inflammation1
Not AvailableCompletedBasic SciencePTSD1
Not AvailableCompletedBasic SciencePosttraumatic Stress Disorders1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedPreventionBlood Diseases / Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT) / Leukemias / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Transplantation, Bone Marrow1
Not AvailableCompletedPreventionEndometriosis of Uterus / Uterine Leiomyomas1
Not AvailableCompletedPreventionGynecological Disease1
Not AvailableCompletedPreventionInflammation Following Cataract Surgery1
Not AvailableCompletedPreventionInflammatory Reaction1
Not AvailableCompletedPreventionPost Lasik Surgery Inflammation1
Not AvailableCompletedPreventionPost Operative Sore Throat1
Not AvailableCompletedPreventionPrevention of Hypersensitivity Reactions to Paclitaxel1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting5
Not AvailableCompletedPreventionTransient Tachypnea of the Newborn1
Not AvailableCompletedPreventionWound Infections1
Not AvailableCompletedScreeningPolycystic Ovaries Syndrome1
Not AvailableCompletedSupportive CareCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Nausea and Vomiting / Neuroblastomas / Testicular germ cell tumour1
Not AvailableCompletedSupportive CareCancers1
Not AvailableCompletedSupportive CareInfertilities1
Not AvailableCompletedSupportive CareLower Extremities Fracture1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedSupportive CareNeoplasms, Malignant1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Effects of Chemotherapy / Prophylaxis of acute chemotherapy induced nausea and vomiting / Sarcomas1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnalgesia, Postoperative1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial / Reactive Airways Disease (RAD)1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBack Pain / Cervical Pain1
Not AvailableCompletedTreatmentCardiac Diseases / Postoperative Complications / Systemic Inflammatory Response Syndrome (SIRS)1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentCentral Retinal Vein Occlusion (CRVO) / Macular Edema (ME)1
Not AvailableCompletedTreatmentChalazion Both Eyes / Chalazion Left Eye, Unspecified Eyelid / Chalazion Right Eye, Unspecified Eyelid / Chalazion Unspecified Eye, Unspecified Eyelid1
Not AvailableCompletedTreatmentClinically Significant Macular Edema / Diabetic Macular Edema (DME) / Macular Edema, Cystoid / Vision Disorders1
Not AvailableCompletedTreatmentCorneal Diseases1
Not AvailableCompletedTreatmentCysticercosis / Epilepsies1
Not AvailableCompletedTreatmentDiabetic Macular Edema (DME) / Vision Disorders1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentEdema / Pain / Trismus2
Not AvailableCompletedTreatmentGeneral Surgery1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentIntraventricular Hemorrhage / Neonatal Mortality / Respiratory Distress Syndrome (RDS)1
Not AvailableCompletedTreatmentLateral Elbow Pain1
Not AvailableCompletedTreatmentLeukemias2
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentNeoplasms, Pancreatic1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentParathyroid Diseases / Thyroid Diseases1
Not AvailableCompletedTreatmentPituitary Adenomas / Pituitary Diseases1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentPost Surgical Pain1
Not AvailableCompletedTreatmentPost-operative Hemorrhage1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting / Tiredness1
Not AvailableCompletedTreatmentPosttraumatic Stress Disorders1
Not AvailableCompletedTreatmentProphylaxis against postoperative nausea and vomiting2
Not AvailableCompletedTreatmentProstate Ca1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentViral Bronchiolitis1
Not AvailableNot Yet RecruitingNot AvailableDiabetic Macular Edema (DME)1
Not AvailableNot Yet RecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome1
Not AvailableNot Yet RecruitingPreventionBilateral Superficial Cervical Block1
Not AvailableNot Yet RecruitingPreventionPostoperative pain / Ureter Stone1
Not AvailableNot Yet RecruitingTreatmentAllergies / Urticarias1
Not AvailableNot Yet RecruitingTreatmentCapsular Contracture, Implant1
Not AvailableNot Yet RecruitingTreatmentDental Research / Pharmaceutical Preparations, Dental1
Not AvailableNot Yet RecruitingTreatmentLow Back Pain (LBP)1
Not AvailableNot Yet RecruitingTreatmentOphthalmology1
Not AvailableNot Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableDiabetic Macular Edema (DME)1
Not AvailableRecruitingNot AvailableLumbosacral Radicular Pain1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)2
Not AvailableRecruitingNot AvailableNon-Infectious Uveitis1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenism / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceFibrosis of the Retina / Macular Edema (ME)1
Not AvailableRecruitingDiagnosticRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableRecruitingOtherProlonged Motor Block / Prolonged Sensory Block / Spinal Anaesthesia1
Not AvailableRecruitingPreventionCesarean Section / Pruritus1
Not AvailableRecruitingPreventionCytokines / Dexamethasone / Pain, Chronic / Thoracic Surgery1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting2
Not AvailableRecruitingSupportive CareCancer, Breast / Prophylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareColonic Neoplasms1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukemia Ph Positive1
Not AvailableRecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAge-related Cataract1
Not AvailableRecruitingTreatmentAnal Condyloma / Fissure in Ano / Hemorrhoids / Rectal Fistulas1
Not AvailableRecruitingTreatmentCataracts1
Not AvailableRecruitingTreatmentEpiretinal Membrane / Macular Edema (ME)1
Not AvailableRecruitingTreatmentEpiretinal Membrane / Macular Edema (ME) / Vitrectomy therapy1
Not AvailableRecruitingTreatmentImpacted Third Molar Tooth1
Not AvailableRecruitingTreatmentLigament Injury / Nerve Entrapment / Rheumatoid Arthritis / Synovitis of osteoarthritis1
Not AvailableRecruitingTreatmentMyopia / Refractive Errors1
Not AvailableRecruitingTreatmentPelvic Organ Prolapse (POP) / Prolapses, Vaginal Vault / Quality of Life1
Not AvailableRecruitingTreatmentPostoperative pain1
Not AvailableRecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
Not AvailableRecruitingTreatmentRupture of Anterior Cruciate Ligament / Tear of Anterior Cruciate Ligament1
Not AvailableRecruitingTreatmentStiffness Following Total Knee Arthroplasty1
Not AvailableRecruitingTreatmentVideo-assisted Thoracic Surgery (VATS) / Video-assisted Thoracoscopic Surgery (VATS)1
Not AvailableRecruitingTreatmentCaudal epidural block therapy1
Not AvailableSuspendedSupportive CareMalignant Ovarian Mixed Epithelial Tumor / Nausea and Vomiting / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
Not AvailableTerminatedOtherLumbar Back Pain / Lumbar Radiculitis / Lumbar Spine Disc Herniation1
Not AvailableTerminatedSupportive CareMalignant Digestive System Neoplasm / Nausea and Vomiting1
Not AvailableTerminatedSupportive CarePain1
Not AvailableTerminatedTreatmentCellulitis1
Not AvailableTerminatedTreatmentEclampsia1
Not AvailableTerminatedTreatmentEpiretinal Membrane / Macular Edema (ME)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableTerminatedTreatmentInflammatory Reaction / Perioperative Morbidity1
Not AvailableTerminatedTreatmentLaparoscopic Colorectal Resection1
Not AvailableTerminatedTreatmentLymphohistiocytosis, Hemophagocytic1
Not AvailableTerminatedTreatmentTotal Knee Arthroplasty (TKA)1
Not AvailableUnknown StatusPreventionAsymptomatic Gallstones Without Cholecystitis / Gallbladder Polyps1
Not AvailableUnknown StatusPreventionNausea / Vomiting1
Not AvailableUnknown StatusPreventionPharyngitis1
Not AvailableUnknown StatusPreventionPonv / Pregnancy1
Not AvailableUnknown StatusPreventionRespiratory Sounds1
Not AvailableUnknown StatusSupportive CareBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Radiation Toxicity1
Not AvailableUnknown StatusTreatmentAnalgesia1
Not AvailableUnknown StatusTreatmentAnalgesia / Postoperative pain1
Not AvailableUnknown StatusTreatmentEarly Gastric Cancer or Gastric Adenoma1
Not AvailableUnknown StatusTreatmentEdema / Pain / Trismus1
Not AvailableUnknown StatusTreatmentFull-frequency Sudden Hearing Loss1
Not AvailableUnknown StatusTreatmentGlaucoma1
Not AvailableUnknown StatusTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Pre-Diabetic1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentRadicular Pain1
Not AvailableUnknown StatusTreatmentRadiculopathy, Cervical1
Not AvailableUnknown StatusTreatmentStridor1
Not AvailableWithdrawnNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableWithdrawnBasic ScienceCoronary Artery Bypass Graft Surgery / Coronary Artery Stenosis1
Not AvailableWithdrawnPreventionRespiratory Complications / Swallowing Disorders1
Not AvailableWithdrawnSupportive CareNeoplasms, Malignant / Ototoxicity1
Not AvailableWithdrawnTreatmentDescemet's Stripping Endothelial Keratoplasty / Endothelial Dystrophy / Posterior Lamellar Keratoplasty / Secondary Bullous Keratopathy1
Not AvailableWithdrawnTreatmentDiabetic Macular Edema (DME)1
Not AvailableWithdrawnTreatmentGlioblastoma Multiforme1
Not AvailableWithdrawnTreatmentPain, Sciatic Block1
Not AvailableWithdrawnTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
ImplantIntracardiac.7 mg
SuspensionAuricular (otic)
Suspension / dropsAuricular (otic)
LiquidDental
LiquidAuricular (otic); Ophthalmic1 mg
TabletOral.5 mg
ElixirOral.5 mg/5mL
SolutionOral.5 mg/5mL
TabletOral.5 mg/1
TabletOral.75 mg/1
TabletOral1 mg/1
TabletOral1.5 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral6 mg/1
Solution, concentrateOral1 mg/mL
LiquidIntramuscular; Intrasynovial; Intravenous10 mg
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous4 mg/5mL
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
InjectionIntramuscular10 mg/mL
InjectionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
Injection, solutionIntra-articular; Intramuscular; Intravenous4 mg/mL
Injection, solutionIntramuscular4 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
Injection, solutionIntravenous4 mg/mL
SolutionOphthalmic1 mg/mL
Solution / dropsOphthalmic1 mg/mL
SolutionIntramuscular; Intrasynovial; Intravenous4 mg
SolutionIntramuscular; Intrasynovial; Intravenous10 mg
LiquidIntra-articular; Intramuscular; Intravenous4 mg
SolutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
SolutionIntramuscular; Intravenous10 mg
LiquidIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
ImplantIntracardiac.5 mg
ImplantIntracardiac0.5 mg
LiquidIntramuscular; Intravenous4 mg
OintmentOphthalmic0.1 %
SuspensionOphthalmic0.1 %
SuspensionOphthalmic1 mg/mL
Solution / dropsOphthalmic
Suspension / dropsOphthalmic
LiquidAuricular (otic); Ophthalmic
TabletOral40 mg
SuspensionOphthalmic
LiquidOphthalmic; Topical.1 %
SolutionAuricular (otic); Ophthalmic0.1 %
ImplantIntravitreal.7 mg/1
ImplantIntravitreal0.7 mg
ImplantIntravitreal700 mcg
ElixirOral0.5 mg
LiquidOral0.5 mg
TabletOral0.5 mg
TabletOral0.75 mg
TabletOral4 mg
TabletOral2 mg
Solution / dropsAuricular (otic); Ophthalmic1 mg
LiquidIntramuscular; Intravenous10 mg
SolutionIntra-articular; Intramuscular; Intravenous4 mg
Solution / dropsAuricular (otic); Ophthalmic.1 %
KitEpidural; Infiltration; Intramuscular; Intravenous
Solution / dropsAuricular (otic); Ophthalmic0.1 %
SolutionAuricular (otic); Ophthalmic
OintmentAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
OintmentTopical
OintmentOphthalmic
Prices
Unit descriptionCostUnit
Ozurdex 0.7 mg implant1554.0USD implant
Maxidex 0.1% Suspension 15ml Bottle97.96USD bottle
Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube87.3USD tube
Maxitrol 5-10000-0.1 Suspension 5ml Bottle75.88USD bottle
Maxidex 0.1% Suspension 5ml Bottle53.57USD bottle
Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)41.99USD box
Dexamethasone micronized powd41.31USD g
Dexamethasone powder21.27USD g
Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle19.99USD bottle
Dexamethasone acetate powd15.12USD g
Dexamethasone sod ph powder14.24USD g
Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial13.99USD vial
Dexamethasone Sodium Phosphate 10 mg/ml4.78USD ml
Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml4.0USD ml
Dexamethasone 0.1% eye drop3.43USD ml
Dexasol 0.1% eye drops3.38USD ml
Maxidex 0.1 % Ointment2.69USD g
Dexamethasone 10 mg/ml vial2.56USD ml
Maxidex 0.1% eye drops2.36USD ml
Dexamethasone Sodium Phosphate 4 mg/ml1.77USD ml
Maxidex 0.1 % Suspension1.73USD ml
Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution1.38USD ml
Pms-Dexamethasone Sodium Phosp 10 mg/ml1.34USD ml
Dexamethasone 4 mg/ml vial1.04USD ml
Dexamethasone 6 mg tablet1.01USD tablet
Dexasone 4 mg Tablet0.86USD tablet
Apo-Dexamethasone 4 mg Tablet0.8USD tablet
Pms-Dexamethasone 4 mg Tablet0.8USD tablet
Ratio-Dexamethasone 4 mg Tablet0.8USD tablet
Dexamethasone 2 mg tablet0.68USD tablet
Dexamethasone 1 mg/1 ml soln0.65USD ml
Dexamethasone 4 mg tablet0.6USD tablet
Dexamethasone 1 mg tablet0.49USD tablet
Pms-Dexamethasone 0.75 mg Tablet0.47USD tablet
Pms-Dexamethasone 2 mg Tablet0.43USD tablet
Dexamethasone 0.5 mg/5ml Elixir0.4USD ml
Dexamethasone 0.75 mg tablet0.38USD tablet
Dexamethasone 1.5 mg tablet0.35USD tablet
Dexamethasone 0.5 mg tablet0.31USD tablet
Apo-Dexamethasone 0.5 mg Tablet0.21USD tablet
Pms-Dexamethasone 0.5 mg Tablet0.2USD tablet
Ratio-Dexamethasone 0.5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8846650No2005-06-042025-06-04Us
US9149486No2002-09-132022-09-13Us
US6359016No2000-08-102020-08-10Us
US6284804No2000-08-102020-08-10Us
US6726918No2000-10-202020-10-20Us
US6899717No2003-11-012023-11-01Us
US8034366No2003-01-092023-01-09Us
US8506987No2003-01-092023-01-09Us
US9012437No2000-10-202020-10-20Us
US8043628No2000-10-202020-10-20Us
US8088407No2000-10-202020-10-20Us
US9283178No2000-10-202020-10-20Us
US9192511No2003-01-092023-01-09Us
US8063031No2000-10-202020-10-20Us
US7033605No2000-10-202020-10-20Us
US7767223No2001-11-282021-11-28Us
US8034370No2003-01-092023-01-09Us
US7795316No2008-08-032028-08-03Us
US8101582No2007-12-192027-12-19Us
US8450287No2007-12-192027-12-19Us
US9345714No2002-09-132022-09-13Us
US9402805No2002-09-132022-09-13Us
US9592242No2000-10-202020-10-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)170-229Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.
water solubility89 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.83HANSCH,C ET AL. (1995)
logS-3.64ADME Research, USCD
Caco2 permeability-4.75ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01ot-0904000000-dbbc479b104fbe981ce7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-c84b561c97b1277fed56
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-b498846e21073040b905
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0900000000-b04e175289861dc518f1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0900000000-b04e175289861dc518f1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01ot-0904000000-dbbc479b104fbe981ce7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-c84b561c97b1277fed56
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-b498846e21073040b905
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006w-0719000000-d4feef3f83ca022aa94d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0913000000-3c8e5afb526637f1e822
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0910000000-57f268bed9b190ee6066
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-cfdda545a27ec16c8b76
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-c70817ad99741f01b675
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-ecbabc9fe90444b14afe
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fr-0019000000-4161bdd8f3deed25b9bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0594000000-bf4495b7906d53ad019d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ds-0980000000-c4e88ec70fa28252f6f7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-0930000000-8022e38d862953c2551b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-1920000000-6f1a7ac153a363c2aa73
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00tf-1910000000-e34981c957b125a39447
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fr-0019000000-285cd2de8c812f1c5e55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0593000000-bd52212afb3af2380901
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ds-0980000000-ff265e4738c79efad9e3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0940000000-818b114d12290dc23743
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-1930000000-9e4283fb9c2780729f55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05dm-1920000000-0f41e220b5d3d1abe699
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-cf986616b1138d5569c7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0009000000-431895662c53cadb563c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4r-0498000000-233b2490f89112ad539e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000j-0791000000-c83a21019f43596e6804
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-0970000000-36eebd63d78f040ae67f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-0940000000-730013951a30cf080ad4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0696000000-1df7921eb1369fef69c4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3960000000-e9ee044790c0655981b1

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:41879) / Pregnane and derivatives [Fig] (C15643)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11. [PubMed:16835395]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  3. Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7. [PubMed:16956592]
  4. Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8. [PubMed:16963802]
  5. Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13. [PubMed:16971495]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Stimulator
General Function
Transcription factor binding
Specific Function
Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional act...
Gene Name
NR0B1
Uniprot ID
P51843
Uniprot Name
Nuclear receptor subfamily 0 group B member 1
Molecular Weight
51717.185 Da
References
  1. Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20. [PubMed:16857744]
  2. Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23. [PubMed:17526944]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Structural molecule activity
Specific Function
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
Gene Name
ANXA1
Uniprot ID
P04083
Uniprot Name
Annexin A1
Molecular Weight
38713.855 Da
References
  1. Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835. [PubMed:16883066]
  2. John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59. [PubMed:17076770]
  3. Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7. [PubMed:17158208]
  4. Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2. [PubMed:17644190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26. [PubMed:17379310]
  2. Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54. [PubMed:17494951]
  3. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28. [PubMed:16054614]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46. [PubMed:11557128]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  3. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32. [PubMed:8845310]
  4. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  7. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
  8. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705. [PubMed:7560060]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14. [PubMed:9929003]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:29